Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy (NCT07656077) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy
30 participantsStarted 2026-08-01
Plain-language summary
The study aims to better characterize intestinal tissue-resident memory T cells (TRM) in people living with HIV-1 receiving suppressive antiretroviral therapy (ART). TRM cells are key components of tissue immunity and may contribute to HIV-1 persistence within the intestinal mucosa, a major viral reservoir. The phenotypic, transcriptomic, and functional characteristics of intestinal CD4+ and CD8+ TRM cells, their susceptibility to HIV-1 infection, and their potential role as viral reservoirs will be investigated. Blood samples and additional colonic biopsies obtained during routine clinically indicated colonoscopy will be collected from HIV-1-infected participants and HIV-seronegative controls.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Group 1: People Living With HIV-1
. Group 2: HIV-Seronegative Controls
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is looking at tissue-resident memory T cells in the intestine — does that mean I would need to have a colonoscopy or intestinal biopsy as part of participating, and what risks would that carry for me specifically?
2Since this trial is listed as 'not yet recruiting,' when is it expected to open, and how would I get on a list to be notified when enrollment begins?
3The study seems focused on understanding how HIV hides in the gut during antiretroviral therapy rather than testing a new treatment — does that mean there's no direct medical benefit to me as a participant, and what exactly would my participation involve?
4Since this is a Phase NA observational study measuring immune cell profiles rather than testing a drug, how does it fit alongside my current antiretroviral regimen, and would anything about participating require me to change or pause my treatment?
5Are there specific criteria around how long someone needs to have been on antiretroviral therapy, or what their viral load needs to be, that would make me a good or poor candidate for this study to discuss with you?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Frequency and Immunophenotypic Profile of Intestinal CD4+ and CD8+ Tissue-Resident Memory T Cells Measured by Multiparameter Flow Cytometry